Quantitative Investment Management LLC Cuts Position in Johnson & Johnson $JNJ

Key Points

• Quantitative Investment Management LLC cut its Johnson & Johnson position by 93.3% in the second quarter, leaving the fund with 1,548 shares worth approximately $393,000. Institutional investors still own 69.55% of JNJ.
• Analysts remain broadly positive, with an average “Moderate Buy” rating and a consensus price target of $272.83; several firms recently raised their targets to between $282 and $294.
• Johnson & Johnson beat quarterly earnings and revenue expectations, reporting $2.90 in EPS and $25.31 billion in revenue, while maintaining its $1.34 quarterly dividend, equivalent to a 2.0% yield.

Quantitative Investment Management LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 93.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,548 shares of the company's stock after selling 21,457 shares during the quarter. Quantitative Investment Management LLC's holdings in Johnson & Johnson were worth $393,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Blueline Advisors LLC purchased a new stake in Johnson & Johnson during the fourth quarter worth about $25,000. Semmax Financial Advisors Inc. lifted its position in shares of Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock valued at $31,000 after buying an additional 72 shares during the last quarter. E Fund Management Hong Kong Co. Ltd. grew its stake in shares of Johnson & Johnson by 946.7% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 157 shares of the company's stock worth $32,000 after acquiring an additional 142 shares during the period. MidAtlantic Capital Management Inc. purchased a new stake in Johnson & Johnson in the 4th quarter worth about $37,000. Finally, Matrix Trust Co increased its stake in shares of Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company's stock worth $38,000 after purchasing an additional 54 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on JNJ. Johnson Rice reissued a "buy" rating on shares of Johnson & Johnson in a report on Monday, August 3rd. The Goldman Sachs Group restated a "buy" rating and set a $282.00 price target on shares of Johnson & Johnson in a research report on Thursday, July 16th. Freedom Capital upgraded Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 16th. Wells Fargo & Company boosted their price objective on shares of Johnson & Johnson from $272.00 to $282.00 and gave the stock an "overweight" rating in a report on Monday, August 3rd. Finally, Morgan Stanley upped their price target on shares of Johnson & Johnson from $284.00 to $294.00 and gave the company an "overweight" rating in a research report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $272.83.

Johnson & Johnson Stock Down 0.7%

Shares of NYSE:JNJ opened at $267.20 on Thursday. Johnson & Johnson has a 1 year low of $173.33 and a 1 year high of $281.07. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The stock's 50-day moving average is $262.88 and its 200 day moving average is $245.62. The company has a market cap of $643.93 billion, a PE ratio of 30.96, a P/E/G ratio of 2.57 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The business had revenue of $25.31 billion for the quarter, compared to analysts' expectations of $25.06 billion. During the same period in the previous year, the firm posted $2.77 EPS. The business's revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a dividend of $1.34 per share. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson's payout ratio is currently 62.11%.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: At the Wells Fargo Healthcare Conference, Johnson & Johnson highlighted growth opportunities in MedTech, with cardiovascular products taking center stage. Management’s focus on high-end, innovative devices supports the company’s longer-term growth outlook. Johnson & Johnson Eyes High-End MedTech Growth as Cardiovascular Takes Center Stage
• Positive Sentiment: JNJ is preparing to present 24 abstracts at Psych Congress 2026, including pivotal Phase 3 CAPLYTA data in bipolar mania and new SPRAVATO analyses. The data could strengthen confidence in the company’s neuropsychiatry pipeline and future pharmaceutical growth. Johnson & Johnson Neuropsychiatry Data
• Positive Sentiment: Jim Cramer characterized the recent weakness as a buying opportunity, reinforcing the view that JNJ’s defensive profile, diversified healthcare operations, and dividend appeal may attract investors during market uncertainty. Cramer Says It’s Time to Buy the Dip on JNJ
• Neutral Sentiment: Analysts and market commentary continue to view JNJ as a defensive stock ahead of inflation data and the Federal Reserve’s next rate decision. That positioning may support demand, but macroeconomic uncertainty is also increasing day-to-day volatility. Defensive Stocks Ahead of CPI and the Fed
• Negative Sentiment: JNJ recently declined more than the broader market, suggesting profit-taking or increased sensitivity to market-wide selling. With shares near their 52-week high and trading at roughly 31 times earnings, valuation may be limiting near-term upside despite solid earnings and full-year EPS guidance. Johnson & Johnson Sees a More Significant Dip Than the Broader Market

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer Taubert sold 15,000 shares of the firm's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. This trade represents a 7.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Elizabeth Forminard sold 15,918 shares of the firm's stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the transaction, the executive vice president directly owned 16,994 shares in the company, valued at approximately $4,367,458. The trade was a 48.37% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 87,569 shares of company stock valued at $23,064,544 over the last 90 days. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.